State of Wisconsin Investment Board acquired a new position in Sage Therapeutics, Inc. (NASDAQ:SAGE) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,991,000. State of Wisconsin Investment Board owned about 0.07% of Sage Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Rhumbline Advisers lifted its holdings in shares of Sage Therapeutics by 9.4% in the 2nd quarter. Rhumbline Advisers now owns 41,138 shares of the biopharmaceutical company’s stock worth $3,276,000 after acquiring an additional 3,551 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in Sage Therapeutics during the 2nd quarter worth approximately $202,000. Schwab Charles Investment Management Inc. increased its stake in Sage Therapeutics by 5.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 138,179 shares of the biopharmaceutical company’s stock worth $11,005,000 after buying an additional 6,739 shares during the period. Canada Pension Plan Investment Board purchased a new stake in Sage Therapeutics during the 2nd quarter worth approximately $175,000. Finally, Pioneer Investment Management Inc. increased its stake in Sage Therapeutics by 126.9% during the 2nd quarter. Pioneer Investment Management Inc. now owns 158,418 shares of the biopharmaceutical company’s stock worth $12,616,000 after buying an additional 88,585 shares during the period.

Several brokerages recently weighed in on SAGE. BidaskClub downgraded shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Needham & Company LLC set a $95.00 target price on shares of Sage Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 4th. HC Wainwright upped their target price on shares of Sage Therapeutics to $86.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Cowen and Company reaffirmed a “buy” rating and set a $100.00 target price on shares of Sage Therapeutics in a research note on Friday, August 4th. Finally, Stifel Nicolaus began coverage on shares of Sage Therapeutics in a research note on Wednesday, August 9th. They set a “buy” rating and a $104.00 target price on the stock. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $89.64.

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) opened at 87.00 on Tuesday. The stock’s market capitalization is $3.26 billion. Sage Therapeutics, Inc. has a 12 month low of $36.01 and a 12 month high of $90.43. The firm has a 50 day moving average of $82.39 and a 200-day moving average of $73.76.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($1.63) by $0.25. During the same quarter in the previous year, the company posted ($1.08) EPS. Analysts forecast that Sage Therapeutics, Inc. will post ($7.38) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “State of Wisconsin Investment Board Acquires New Holdings in Sage Therapeutics, Inc. (SAGE)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/05/state-of-wisconsin-investment-board-acquires-new-holdings-in-sage-therapeutics-inc-sage.html.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.